ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

8967 reported adverse events

Drug classes: Cytochrome P450 3A Inhibitor [EPC] Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC] Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE:

# Side effect Count
0 BONE DENSITY DECREASED 4603
1 RENAL INJURY 3312
2 SKELETAL INJURY 3030
3 CHRONIC KIDNEY DISEASE 2519
4 TOOTH LOSS 2488
5 BONE LOSS 2161
6 OSTEONECROSIS 2117
7 RENAL FAILURE 2087
8 MULTIPLE FRACTURES 1980
9 TOOTH INJURY 1979
See all common reactions for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TOOTH INJURY 1979 0.4554
1 SKELETAL INJURY 3030 0.2927
2 BONE DEMINERALISATION 175 0.1653
3 BONE DENSITY DECREASED 4603 0.1468
4 BONE LOSS 2161 0.1436
5 MULTIPLE FRACTURES 1980 0.1204
6 TOOTH LOSS 2488 0.1199
7 RENAL INJURY 3312 0.1114
8 BONE DENSITY ABNORMAL 277 0.0740
9 OSTEOPENIA 1092 0.0719
See all enriched reactions for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE